Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

Core Insights - TG Therapeutics is focused on developing treatments for B-cell diseases, with its flagship product BRIUMVI targeting relapsing multiple sclerosis (RMS) [1] Financial Performance - Goldman Sachs updated its rating for TG Therapeutics to Neutral, maintaining a hold recommendation, with the stock price at $29.54 and a raised price target from $37 to $39 [2][6] - TG Therapeutics projects FY25 revenue to reach approximately $616 million, an 87% increase from $329 million in FY24, and anticipates FY26 revenue between $875 million and $900 million [3][6] - BRIUMVI is expected to contribute around $594 million in product revenue for FY25, with FY26 projections ranging from $825 million to $850 million [4][6] Market Position - Despite a 7.7% decline in shares over the past year, TG Therapeutics remains optimistic about long-term revenue growth driven by BRIUMVI's commercial performance and market share capture [5]

Key Takeaways TGTX shares rose after preliminary Q4 and full-year 2025 revenues topped company guidance.TGTX expects 2026 revenues of $875M to $900M, including $825M to $850M from U.S. Briumvi sales.TGTX plans multiple 2026 milestones, including ENHANCE data, subcutaneous Briumvi results, and azer-cel data.TG Therapeutics’ (TGTX) shares rose nearly 7% in after-hours trading, following the release of preliminary fourth-quarter and full-year 2025 results on Jan. 13, which beat expectations.TGTX issued bullish ...

Core Insights - U.S. stocks experienced a decline, with the Nasdaq Composite dropping over 200 points on Wednesday [1] - TG Therapeutics Inc reported preliminary total global revenue for fiscal year 2025 of approximately $616 million, leading to a significant increase in its stock price [2] Company Performance - TG Therapeutics reported U.S. net product revenue for BRIUMVI of approximately $182 million for Q4 and $594 million for the full year, with these figures being unaudited [2] - TG Therapeutics shares surged by 11.6% to $31.10 following the revenue announcement [2] Other Notable Stock Movements - Rich Sparkle Holdings Ltd shares increased by 13.5% to $95.31 [3] - Cerus Corp gained 12.7% to $2.84 [3] - Clover Health Investments Corp saw an 11.2% rise to $2.82, driven by year-over-year membership growth in its Medicare Advantage PPO plans [3] - Highpeak Energy Inc shares rose by 8.3% to $5.07 [3] - Nutrien Ltd gained 7% to $65.62 after an upgrade from Morgan Stanley analyst Vincent Sinisi, with a price target increase from $70 to $77 [3]

Market Overview - U.S. stock futures declined on Wednesday following a lower close on Tuesday, with major benchmark indices showing a downward trend [1] - The Consumer Price Index (CPI) rose 2.7% year over year in December, matching previous readings and economists' estimates, while core CPI was slightly below expectations at 2.6% [1] Economic Indicators - The 10-year Treasury bond yielded 4.17%, and the two-year bond yielded 3.52%, indicating investor sentiment towards interest rates [2] - The CME Group's FedWatch tool indicates a 97.2% likelihood of the Federal Reserve maintaining current interest rates in January [2] Stock Performance - Major indices showed the following performances: Dow Jones -0.15%, S&P 500 -0.16%, Nasdaq 100 -0.16%, Russell 2000 +0.14% [3] - SPDR S&P 500 ETF Trust (NYSE:SPY) was down 0.15% at $692.73, while Invesco QQQ Trust ETF (NASDAQ:QQQ) declined 0.20% to $625.00 in premarket trading [3] Company Focus - Wells Fargo & Co. (NYSE:WFC) was down 0.81% in premarket trading, with expected quarterly earnings of $1.67 per share on revenue of $21.65 billion [7] - BP PLC (NYSE:BP) dropped 1.84% after announcing potential writedowns of up to $5 billion in its energy transition businesses [7] - WeRide Inc. ADR (NASDAQ:WRD) rose 1.59% after launching the Robotaxi Mini Program "WeRide Go" on Tencent WeChat [7] Analyst Insights - Professor Jeremy Siegel anticipates a strong 2026 driven by productivity growth, with a surprising fourth-quarter GDP growth estimate of 5.4% [10] - Siegel suggests a shift in stock market leadership away from mega-cap technology stocks, predicting double-digit returns from small-cap stocks and non-tech cyclicals [11] Upcoming Economic Data - Delayed reports on U.S. retail sales and producer price index are scheduled for release at 8:30 a.m. ET [14] - Additional economic data, including business inventories and existing home sales, will be released at 10:00 a.m. ET [14] Commodities and Global Markets - Crude oil futures fell by 0.98% to around $60.57 per barrel, while gold prices rose by 0.93% to approximately $4,629.12 per ounce [16] - Bitcoin traded 3.32% higher at $94,969.36 per coin [16] Global Market Performance - Asian markets closed mixed, with India's Nifty 50 and China's CSI 300 indices falling, while Australia's ASX 200, Japan's Nikkei 225, Hong Kong's Hang Seng, and South Korea's Kospi indices rose [17]

Core Viewpoint - U.S. stock futures are trading lower, with several companies expected to report quarterly earnings, drawing investor attention [1] Company Earnings Expectations - Bank of America Corp (NYSE:BAC) is anticipated to report quarterly earnings of 96 cents per share on revenue of $27.87 billion, with shares slipping 0.1% to $54.51 in after-hours trading [1] - Citigroup Inc (NYSE:C) is expected to post quarterly earnings of $1.68 per share on revenue of $20.53 billion, with shares falling 0.1% to $116.15 in after-hours trading [1] - Wells Fargo & Co (NYSE:WFC) is projected to report quarterly earnings of $1.67 per share on revenue of $21.65 billion, with shares decreasing 0.2% to $93.38 in after-hours trading [1] Company Updates - TG Therapeutics, Inc. (NASDAQ:TGTX) provided preliminary fourth quarter revenue estimates, expecting U.S. net product revenue of approximately $182 million for Q4 and $594 million for the full year of 2025, with total global revenue for 2025 expected to be around $616 million [1] - Gelteq Ltd. (NASDAQ:GELS) reported positive preclinical results for its cannabinoid oral gel delivery platform, leading to a significant share price increase of 69.3% to $1.41 in after-hours trading [1]

Corporate Updates - China SXT Pharmaceuticals, Inc. (SXTC) surged 17.40% to $0.12 after announcing a registered direct offering valued at about $10 million, selling 66,666,666 Class A ordinary shares at $0.15 per share, strengthening its balance sheet and fueling investor optimism [2] - Rapid Micro Biosystems, Inc. (RPID) advanced 8.55% to $3.30 following the release of preliminary unaudited fourth-quarter and full-year 2025 revenue results, sparking a positive reaction in extended trading [3] - TG Therapeutics, Inc. (TGTX) gained 6.99% to $29.82 after announcing preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for the fourth quarter and full year 2025, along with 2026 financial guidance and development milestones [4] - argenx SE (ARGX) rose 2.00% to $826.72 after the FDA accepted for priority review a supplemental Biologics License Application for VYVGART, with a PDUFA target action date of May 10, 2026, indicating potential for expanded indications [5] - Clene Inc. (CLNN) edged higher by 0.98% to $5.15 after announcing an in-person Type C Meeting with the FDA, representing an important step in advancing its pipeline [6] Market Reactions - Cosmos Health Inc. (COSM) climbed 6.09% to $0.4961 despite no company-specific news, highlighting speculative interest and momentum trading in the micro-cap healthcare space [3] - Entera Bio Ltd. (ENTX) gained 4.11% to $1.52 in after-hours trading, reflecting investor activity around small-cap biotech names despite no new corporate updates [7]

Company Overview - TG Therapeutics was founded in 2012, focusing on B-cell-mediated diseases, including autoimmune diseases, neuroinflammatory conditions, and cancer [3] - The company is primarily focused on multiple sclerosis (MS) and has one approved drug, BRIUMVI, which is approaching blockbuster status [3] Product Information - BRIUMVI is an anti-CD20 monoclonal antibody that was approved in late December 2022 and launched in January 2023 [4] - The drug is not only available in the U.S. but has also been launched globally [4] Clinical Development - TG Therapeutics has two pivotal trials ongoing to expand the utilization and total addressable market for BRIUMVI [3] - The company has three additional programs under development [3]

TG Therapeutics (NasdaqCM:TGTX) FY Conference January 13, 2026 04:30 PM ET Company ParticipantsMichael Weiss - CEOConference Call ParticipantsBrian Cheng - Senior Biotech AnalystBrian ChengGood afternoon, everyone. Thanks for joining us for another session at the 44th J.P. Morgan Healthcare Conference. I'm Brian Cheng. I'm one of the senior biotech analysts here at the firm. On stage, we have Mike Weiss, who is the CEO of TG Therapeutics. I'll now pass the mic to their CEO for a short presentation, followed ...